UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018791
Receipt number R000021743
Scientific Title Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation.
Date of disclosure of the study information 2015/08/25
Last modified on 2023/06/09 06:17:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation.

Acronym

Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation for high risk MDS.
(KSGCT1501, MDS-AZA-P1)

Scientific Title

Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation.

Scientific Title:Acronym

Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation for high risk MDS.
(KSGCT1501, MDS-AZA-P1)

Region

Japan


Condition

Condition

Myelodysplastic syndrome(MDS)

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Dose finding study of maintenance therapy with Azacitidine after allogeneic hematopoietic stem cell transplantation.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Estimate of feasible initial dose
Completion rate of total 4 cycles

Key secondary outcomes

(1) Incidence of dose limiting toxicity
(2) Incidence of adverse events
(3) Time to progression


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Azacitidine 20 mg/m2/day, 5days

Interventions/Control_2

Azacitidine 30 mg/m2/day, 5days

Interventions/Control_3

Azacitidine 40 mg/m2/day, 5days

Interventions/Control_4

Azacitidine 50 mg/m2/day, 5days

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Age between 18 and 65 years-old
(2) After receiving allogeneic hematopoietic stem cell transplant for high-risk MDS (IPSS int-2 or high) in FAB classification.
(3) Engraftment with sufficient hematopoiesis
(4) Remission after allogeneic stem cell transplant
(5) Between days 40 and 180 post-transplantation
(6) ECOG performance status score 0 to 2
(7) Enough organ function
(8) With written informed consent

Key exclusion criteria

(1) Allergic to azacitidine
(2) With active uncontrollable infectious diseases
(3) With severe mental disorder
(4) With severe acute GHVD Grade III to IV
(5) Requiring 2nd line therapy for acute GVHD due to unsuccessful 1st line therapy
(6) Uncontrollable chronic GVHD
(7) Under treatment of anti-CMV drug
(8) Those evaluated ineligible by attending doctors

Target sample size

15


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shin-ichiro Okamoto

Organization

Kanto Study Group for Cell Therapy

Division name

Chairman

Zip code


Address

Tokyo

TEL

03-6225-2040

Email

ksgctdc@ksgct.net


Public contact

Name of contact person

1st name
Middle name
Last name Yuho Najima

Organization

Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital

Division name

Hematology division

Zip code


Address

3-18-22 Honkomagome Bunkyo-ku Tokyo, 113-8677, Japan.

TEL

03-3823-2101

Homepage URL


Email

yuhonajima@cick.jp


Sponsor or person

Institute

Kanto Study Group for Cell Therapy

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 06 Month 07 Day

Date of IRB

2015 Year 08 Month 20 Day

Anticipated trial start date

2015 Year 08 Month 25 Day

Last follow-up date

2019 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

https://doi.org/10.1007/s00277-022-04981-x
Najima Y, Tachibana T, Takeda Y et al. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. Ann Hematol. 2022 Dec;101(12):2719-2729.


Management information

Registered date

2015 Year 08 Month 25 Day

Last modified on

2023 Year 06 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021743


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name